245 related articles for article (PubMed ID: 11929086)
1. Does smoking increase relapse rates in Graves' disease?
Kimball LE; Kulinskaya E; Brown B; Johnston C; Farid NR
J Endocrinol Invest; 2002 Feb; 25(2):152-7. PubMed ID: 11929086
[TBL] [Abstract][Full Text] [Related]
2. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
Glinoer D; de Nayer P; Bex M;
Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
[TBL] [Abstract][Full Text] [Related]
3. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
[No Abstract] [Full Text] [Related]
5. Smoking and risk of Graves' disease.
Prummel MF; Wiersinga WM
JAMA; 1993 Jan; 269(4):479-82. PubMed ID: 8419666
[TBL] [Abstract][Full Text] [Related]
6. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
Rotondi M; Cappelli C; Pirali B; Pirola I; Magri F; Fonte R; Castellano M; Rosei EA; Chiovato L
J Clin Endocrinol Metab; 2008 Oct; 93(10):3985-8. PubMed ID: 18664537
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
Wang PW; Liu RT; Tung SC; Chien WY; Lu YC; Chen CH; Kuo MC; Hsieh JR; Wang ST
J Formos Med Assoc; 1998 Sep; 97(9):619-25. PubMed ID: 9795530
[TBL] [Abstract][Full Text] [Related]
8. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
[TBL] [Abstract][Full Text] [Related]
9. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
[TBL] [Abstract][Full Text] [Related]
10. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
11. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
12. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
14. Remission of Graves' hyperthyroidism treated with methimazole.
Bolaños F; González-Ortiz M; Durón H; Sánchez C
Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the medical treatment of Graves' disease (GD)].
Peixoto MC; Coeli CM; Vaisman M
Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
[TBL] [Abstract][Full Text] [Related]
17. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.
Masiello E; Veronesi G; Gallo D; Premoli P; Bianconi E; Rosetti S; Cusini C; Sabatino J; Ippolito S; Piantanida E; Tanda ML; Chiovato L; Wiersinga WM; Bartalena L
J Endocrinol Invest; 2018 Dec; 41(12):1425-1432. PubMed ID: 29946800
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
Michelangeli V; Poon C; Taft J; Newnham H; Topliss D; Colman P
Thyroid; 1998 Feb; 8(2):119-24. PubMed ID: 9510119
[TBL] [Abstract][Full Text] [Related]
19. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
[TBL] [Abstract][Full Text] [Related]
20. [Clinical epidemiology of Basedow's disease in Belgium].
Glinoer D
Rev Med Brux; 2000 Sep; 21(4):A296-9. PubMed ID: 11068483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
